Naimish Patel

Breakthrough Study Shows Amlitelimab’s Long-lasting Effectiveness in Atopic Dermatitis Treatment

(IN BRIEF) In a groundbreaking Phase 2b study, amlitelimab demonstrates remarkable potential in maintaining treatment response for patients with moderate…

2 months ago

Sanofi’s Dupixent Receives FDA Approval for Pediatric Eosinophilic Esophagitis (EoE) Treatment

(IN BRIEF) The U.S. Food and Drug Administration (FDA) has granted approval for Dupixent® (dupilumab) to treat pediatric patients aged…

3 months ago

Dupixent Shows Remarkable Efficacy in Reducing COPD Exacerbations in Second Phase 3 Trial

(IN BRIEF) In a significant development, the second investigational Phase 3 trial of Dupixent® (dupilumab) for chronic obstructive pulmonary disease…

5 months ago

Zweite Phase-3-Studie für Dupixent/Dupilumab: Das Medikament kann Juckreiz und Hautläsionen bei Patienten mit unkontrollierter Prurigo nodularis deutlich reduzieren

Dupixent ist das erste und einzige Medikament mit positiven Phase-3-Ergebnissen bei Prurigo nodularis, was den potenziellen Nutzen einer gezielten Behandlung…

2 years ago

Second Phase 3 trial for Dupixent/Dupilumab: the medicine can significantly reduce itch and skin lesions in patients with uncontrolled prurigo nodularis

Dupixent is the first and only medicine to demonstrate positive Phase 3 results in prurigo nodularis, confirming the potential benefit…